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Abstract The purpose of this study was to identify genes
that associated with higher ability of metastasis and
chemotherapic resistance in epithelial ovarian carcinoma
(EOC) cells. An oligonucleotide microarray with probe sets
complementary to 41,000? unique human genes and tran-
scripts was used to determine whether gene expression
profile may differentiate three epithelial ovarian cell lines
(RMG-I-C, COC1 and HO8910) from their sub-lines
(RMG-I-H, COCI/DDP and HO8910/PM) with higher
ability of metastasis and chemotherapic resistance. Quan-
titative real-time PCR and immunohistochemical staining
validated the microarray results. Hierarchic cluster analysis
of gene expression identified 49 genes that exhibited C2.0-
fold change and P value B0.05. Highly differential
expression of GCET2, NLRP4, FOXP1 and SNX29 genes
was validated by quantitative PCR in all cell line samples.
Finally, FOXP1 was validated at the protein level by
immunohistochemistry in paraffin embedded ovarian
tissues (i.e., for metastasis, 15 primary EOC and 10
omental metastasis [OM]; for chemoresistance, 13 sensi-
tive and 13 resistant EOC). The identification of higher
ability of metastasis and chemotherapic resistance-associ-
ated genes may provide a foundation for the development
of new type-specific diagnostic strategies and treatment for
metastasis and chemotherapic resistance in epithelial
ovarian cancer.
Keywords Gene expression profile  Metastasis-
associated gene  Chemoresistance-associated genes 
Microarray  Epithelial ovarian carcinoma  FOXP1
Introduction
Epithelial ovarian cancers (EOC) are high aggressive
tumors associated with high mortality and morbidity in
gynecology. Although the 5-year survival rate is 90 % for
women with early-stage ovarian cancer and postoperative
introduction of paclitaxel drug have improved the 5-year
survival rate for advanced-stage ovarian cancer, patients
with this cancer have a 5-year survival rate of only 30 %
[1]. Standard therapy includes cytoreductive surgery with
first-line combination chemotherapy, 75 % of patients
initially respond to conventional chemotherapy; however,
80 % of these women eventually relapse and die from
chemotherapy resistant disease. Thus, to understand the
molecular basis of epithelial ovarian cancer metastasis and
chemotherapeutic resistance is of vital importance and may
have the potential to improve significantly the development
of more specific and effective treatment against EOC.
Comprehensive, high-throughput technologies such as gene
expression microarrays have provided powerful tools for
this purpose.
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In the present study, the whole human genome oligo
microarray was used to investigate the differential
expression genes (DEGs) in the human ovary cancer cell
lines RMG-1-C, COC1, HO8910 and their high malignant
and chemoresistant sub-cell lines RMG-I-H, COC1/DDP
and HO8910/PM. Hierarchical clustering of genes by the
expression level of the DEGs was performed. The potential
functions of the DEGs were analyzed by Gene Ontology
(GO) and pathway enrichment analyses. In addition, the
interaction relationships between these DEGs were inves-
tigated by regulatory network. We hope these metastasis
and chemotherapy resistance-associated genes may be used
for early detection of epithelial ovarian cancer and for




The human ovarian cancer cell strain RMG-1 was the
courtesy of Doctor Iwamori Masao of Kinki University in
Japan. We transfected the gene of extrinsic a1,2-fucosyl
transferase (a1,2-FT) into RMG-1 to create cell line RMG-
1-H with high expression of Lewis (y) and a1,2-fucosyl
transferase [2, 3], and we discovered that compared with
the empty plasmid vector transfected cell line RMG-1-C,
cell line RMG-1-H showed enhanced cellular malignant
biological behaviors, such as enhanced metastasis and
proliferation [4], adhesion [5] and multiple drug resistance
[6].
Human ovarian cancer cell lines HO-8910 and HO-8910
PM (a highly metastatic cell line derived from HO-8910)
were purchased from the Cell Bank of Type Culture Col-
lection of the Chinese Academy of Sciences (Shanghai,
China) [7], human ovarian cancer cell lines COC1 and
COC1/DDP (a platinum resistance cell line derived from
COC1) were purchased from the China Center for Type
Culture Collection (Wuhan, China). Cells were cultured in
RPMI-1640 medium supplemented with 100 units/mL
penicillin/streptomycin and 10 % fetal bovine serum (FBS)
and maintained in an incubator at 37 C under a humidified
atmosphere of 5 % CO2. COC1/DDP cells were cultured in
RPMI-1640 medium containing 0.5 lg/mL cisplatin
(Sigma, St. Louis, MO, USA) to maintain the drug resistant
phenotype. The cell lines and labels in this experiment are
listed in Table 1.
Total RNA extraction and gene chip hybridization
Total RNA was extracted from all 6 cell line samples with
TRIZOL reagent (Life Technologies, Inc, Carlsbad, CA)
and further purified with RNeasy Min-elute Clean-up
Columns (Qiagen, Valencia, CA), as described by the
manufacturers. Optical density for each sample of RNA
was measured at OD 260 nm and OD 280 nm using
NanoDrop ND-1000 (NanoDrop Technologies, Wilming-
ton, DE, USA). All RNA samples isolated OD260/280 ratio
should be close to 2.0 for pure RNA (ratios between 1.8
and 2.1 are acceptable). The OD A260/A230 ratio should
be more than 1.8. Each isolated RNA sample was subjected
to further quality check to ensure integrity of RNA with
Agilent RNA 6000 Nano LabChip using Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA,
USA). All RNA samples were verified to be intact with
distinct 28S and 18S RNA bands at a ratio of approxi-
mately 2:1 and a RNA integrity number (RIN) [ 7.
The samples were amplified and labeled using the Ag-
ilent Quick Amp labeling kit and hybridized with Agilent
whole genome oligo microarray in Agilent’s SureHyb
Hybridization Chambers in accordance with the manufac-
turer’s instructions. This array contains 41,000? unique
human genes and transcripts represented, all with public
domain annotations, content sourced from RefSeq, Gold-
enpath Ensembl Unigene Human Genome (Build 33) and
GenBank databases, over 70 % of the represented probes
are validated by Agilent’s laboratory validation process,
4 9 44 K slide formats printed using Agilent’s 60-mer
SurePrint technology. After hybridization and washing, the
processed slides were scanned with the Agilent DNA
microarray scanner (part number G2505B) using settings
recommended by Agilent Technologies.
Data analysis and clustering
Agilent Feature Extraction Software (version 10.5.1.1) was
used to extract the signal intensity values from each gene
chip, and the resulting text files were imported into the
Agilent GeneSpring GX software (version11.0) for further
analysis. The 6-microarray data sets were normalized in
GeneSpring GX using the Agilent FE one-color scenario
(mainly median normalization), and genes marked present
or marginal in all samples were chosen for data analysis.
DEGs were identified through fold-change screening
comparing between cell lines group A, B, C and cell lines
group 1, 2 and 3. The threshold used to screen up or down-
regulated genes is fold change C2.0 and P value B0.05. A
scatter plot was made to visualizingly assess the variation
Table 1 Cell line samples description
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between chips. A hierarchical clustering and volcano plot
were performed to visualizingly show a distinguishable
gene expression profiling among samples.
Validation for gene expression by quantitative real-time
polymerase chain reaction
Real-time polymerase chain reaction (RT-PCR) was per-
formed in triplicate with primer sets and probes that were
specific for 4 selected genes that were found to be signif-
icantly differentially expressed. These 4 genes were 2 up-
regulated genes: GCET2, CFTR and 2 down-regulated
genes: FOXP1, GARS. cDNA was synthesized using ran-
dom primers (hexamers) and Oligo 18dT and Superscript II
Reverse Transcriptase (Invitrogen). Real-time PCR was
performed on Roche LightCycler 480 sequence detection
system, using the following amplification conditions:
5 min, 95 C; followed by 40 cycles of 15 s 95 C, 1 min
60 C and 20 s 72 C. CT values were determined using
the IQ5 software (Bio-Rad). The primers mostly were
searched from PrimerBank (http://pga.mgh.harvard.edu/
primerbank/ index.html). Primers of target genes are listed
in Table 2. The comparative threshold cycle method was
used for the calculation of amplification fold, as specified
by the manufacturer. The housekeeping gene glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) was used
to normalize the quantity of complementary DNA that was
used in the PCR reactions.
Immunohistochemistry on paraffin embedded tissues
To evaluate protein expression levels for 1 of the 49 genes
that was found to be different regulated, in consideration of
a further study, immunohistochemical staining for FOXP1
was performed on ovarian tissue samples. 29 cases of
primary ovarian cancer samples and 25 cases of omental
metastatic (OM) ovarian cancer samples were collected
from Shengjing Hospital of China Medical University in
2013, the histopathological diagnoses were determined
using the WHO criteria. In our previous studies, we have
established a set of ovarian cancer chemotherapeutic sen-
sitive and resistant paraffin embedded samples [8, 9], and
we randomly selected 40 samples in sensitive and 30
samples in resistant group for FOXP1 staining. There was
no statistical difference between these two groups of
ovarian samples in age, pathological subtype, lymph node
metastasis or residual tumor size (data not shown). FOXP1
staining was performed using JC12 mouse anti-human
monoclonal antibodies (diluted 1:40, JC12 was kindly
provided by Alison H. Banham, University of Oxford, UK
[10]) using the Envision detection kit (Maixin. Bio China).
Positive myoepithelial cell staining and negative stromal
cell staining in breast carcinoma were used as internal
positive and negative controls, respectively. FOXP1
nuclear expression was scored using the following system:
negative = 0; weak/focal = 1; strong focal/widespread
moderate staining = 2; or strong/widespread staining = 3.
Tumors that scored 2 or 3 were considered positive for
FOXP1 nuclear staining. Survival analysis was performed
on those patients, and the overall survival (OS) time was
defined from the date of surgery (earliest was in July, 2004)
to the date of death or the last follow-up (Jun, 2014).
Enrichment analysis of DEGs
Gene Set Analysis Toolkit (Gestalt) tool was used to do
enrichment analysis on the DEGs in three sections of
function, biological process and molecular composition.
Gestalt is a suite rich of analysis of biologically relevant
content collecting eight species, including human, rat,
mouse and other data from various different public data
resources, such as NCBI, Ensemble, Gene Ontology
(GO) and Kyoto Encyclopedia of Genes and Genomes
(KEGG).
Table 2 Gene-specific primers
used for validation
F forward primer, R reverse
primer
Gene name GenBank accession number Primer sequence (50-30) Amplicon size (bp)
GCET2 NM_152785 F: ACCCTCATCAATCATCGGGTT 122
R: TCAGTCTCAGTTCCTCCCAAG
CFTR NM_000492 F: TGCCCTTCGGCGATGTTTTT 127
R: GTTATCCGGGTCATAGGAAGCTA
FOXP1 NM_032682 F: TCCCGTGTCAGTGGCTATGAT 226
R: CTCTTTAGGCTGTTTTCCAGCAT
GARS NM_002047 F: TTGGCCCAGCTTGATAACTATG 103
R: ACACTGGAGGGGATAGATCATTT
GAPDH NM_001256799 F: ACAACTTTGGTATCGTGGAAGG 101
R: GCCATCACGCCACAGTTTC
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Construction of gene regulatory network
The gene regulatory network was visualized by Cytoscape
[11]. Proteins in the network served as the ‘‘nodes,’’ and
each pairwise protein interaction (referred to as edge) was
represented by an undirected link. The property of the
network was analyzed with the plug-in network analysis.
Statistics
Statistical analysis was performed using Graphpad Prism 6.0e
Software for Mac OS X (GraphPad Software, La Jolla Cali-
fornia USA, www.graphpad.com). Student’s t test was
employed for comparison between two groups and one-way
ANOVA with Tukey’s post hoc test was used for comparison
between more than two groups. As to the analysis of quanti-
tative RT-PCR result, data were expressed as mean ± SEM to
compare on mRNA expression between different groups. The
Chi square and Kaplan–Meier survival analysis were applied
to analyze the nuclear expression of FOXP1. For these tests, a
P value of\0.05 was considered statistically significant.
Results
Gene expression analysis and clustering
The expression profiles of all the samples passed the
microarray quality control (Table 3); a scatter plot was
constructed with a two-dimensional rectangular coordinate
plane (Fig. 1).
Using hierarchical clustering map analysis with probe
sets, the DEGs were identified in visualization, which
readily distinguished the 2 groups as shown in Fig. 2. The
volcano plot of DEGs revealed a total of 49 probe sets that
showed a C2.0-fold change and P value B0.05, as shown in
Fig. 3. Of 49 genes, 14 genes were found to be up-regu-
lated and 35 genes down-regulated (Table 4).
Validation of gene expression results by using
quantitative RT-PCR
Four highly differentially expressed genes (i.e., GCET2,
CFTR, FOXP1 and SNX29) were selected for quantitative
RT-PCR analysis as shown in Fig. 4. These results were in
good agreement with the microarray data, confirming the
reliability of the microarray results.
Validation of protein expression
by immunohistochemical staining
To confirm gene expression results at the protein level,
immunohistochemistry for FOXP1 was carried out on all
paraffin embedded samples. For metastasis, as shown in
Table 5, FOXP1 nuclear positive staining in EOC was
detected in 12 of 29 EOC samples (41.4 %), while only 4
of 25 OM samples (16.0 %) showed positive nuclear
staining for FOXP1 (P = 0.042). For chemotherapeutic
resistance, as shown in Table 6 and depicted in Fig. 5,
Table 3 Sample qualification Sample ID OD260/280 OD260/230 Concentration (ng/lL) RIN 28S/18S Results
A 2.06 1.9 1,126.89 8.9 1.8 Qualified
B 2.06 2.09 1,692.74 8.7 1.9 Qualified
C 2.06 2.19 1,092.17 8.0 1.8 Qualified
1 2.07 1.95 1,431.45 8.6 1.7 Qualified
2 2.07 2 1,428.15 8.5 1.8 Qualified
3 2.07 2.14 1,024.49 8.9 2.1 Qualified
Fig. 1 Representative scatter plot of changes in gene expression
levels. Scatter plot is a visualization that is useful for assessing the
variation (or reproducibility) between chips. All detected probe point
values on the chip were plotted. The central diagonal lines were used
to classify gene expression levels into three groups: group I,[twofold
change increase in gene expression; group II, gene expression levels
within a twofold change; and group III,[twofold change decrease in
gene expression
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FOXP1 nuclear positive staining in sensitive group was
detected in 17 of 40 sensitive samples (42.5 %), while only
5 of 30 resistant samples (16.7 %) showed positive nuclear
staining for FOXP1 (P = 0.021). A Kaplan–Meier survival
analysis was applied to further investigate the effect of
FOXP1 protein on ovarian cancer patients, as shown in
Fig. 6, positive nuclear staining of FOXP1 was an inde-
pendent risk factor and strongly correlated with prognosis.
GO function analysis and Signal pathway result
of differential genes
Significant bioprocesses of the DEGs, gene expression,
biopolymer biosynthetic process, macromolecule biosyn-
thetic process, cAMP-mediated signaling, nucleic acid
metabolic process, transcription and so on (Table 7). A
total of 176 KEGG pathways were enriched for the 49
DEGs, including 20 significantly enriched pathways
(Table 8), such as P450 hydroxylations, HIF-1-alpha
transcription factor network, mechanism of acetaminophen
activity and toxicity, cystic fibrosis transmembrane con-
ductance regulator (CFTR) and beta 2 adrenergic receptor
(B2AR) pathway, alpha6beta4integrin, negative regulation
of the PI3K/AKT network.
Establishment of regulatory network for the DEGs
In order to further investigate the global expression
occurring and to define how individual up- or down-
regulated genes interact with each other to have a
coordinated role, we identified potential networks for
these DEGs (Fig. 7). Among the 49 DEGs, 20 were
involved in the establishment of regulation network, of
which 4 were up-regulated and 16 were down-regulated.
A total of 21 transcription factors (TFs) were predicted,
in which UBC and EP200 are the most connected pre-
dicted hub genes.
Discussion
Ovarian cancer has the highest mortality rate of all gyne-
cologic cancers, and 75 % of patients diagnosed with
ovarian cancer are already at an advanced stage.
Fig. 2 Hierarchical clustering map of DEGs. The result of hierar-
chical clustering on conditions shows a distinguishable gene expres-
sion profiling among samples
Fig. 3 Volcano plot of DEGs. The vertical lines correspond to
twofold up and down, respectively, and the horizontal line represents
a P value of 0.05. So the red point in the plot represents the
differentially expressed genes with statistical significance
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Table 4 Differentially








GCET2 NM_001008756 Germinal center expressed transcript 2 3.25461 0.01955
TMEFF1 NM_003692 Transmembrane protein with EGF-like and two
follistatin-like domains 1
2.48936 0.02476
PTTG3 NR_002734 Pituitary tumor-transforming 3 on chromosome 8 2.39659 0.00859
CFTR NM_000492 Cystic fibrosis transmembrane conductance
regulator isoform 36
2.37741 0.02794
MS4A6A NM_022349 Membrane-spanning 4-domains, subfamily A,
member 6A
2.32408 0.02803
FFAR2 NM_005306 Free fatty acid receptor 2 2.26184 0.01446
BX648831 BX648831 Poly(A) binding protein, cytoplasmic 4-like 2.25877 0.01799
GPRC6A NM_148963 G-protein-coupled receptor, family C, group 6,
member A
2.17761 0.02608
SLC25A42 NM_178526 Solute carrier family 25, member 42 2.13807 0.02038
SVEP1 AK027870 Sushi, von Willebrand factor type A, EGF and
pentraxin domain containing 1
2.1106 0.00132
NLRP4 NM_134444 NLR family, pyrin domain containing 4 2.10449 0.00205
GLP1R NM_002062 Glucagon-like peptide 1 receptor 2.09506 0.02839
LOC643406 BC031676 Hypothetical protein LOC643406 2.04176 0.01908
FLJ14816 BC113708 Hypothetical protein FLJ14816 2.01485 0.04223
Down-regulated genes
RPL28P1 XR_019242 Ribosomal protein L28 pseudogene 1 3.80897 0.01208
RPL23A NM_000984 Ribosomal protein L23a 3.35458 0.04575
RPL13AP3 BC067891 Ribosomal protein L13a pseudogene 3 3.0956 0.00275
COX19 NM_001031617 COX19 cytochrome c oxidase assembly homolog
(S. cerevisiae)
2.85475 0.01561
RBMX NM_002139 RNA binding motif protein, X-linked 2.77763 0.04326
LOC341412 CA455253 Hypothetical LOC341412, pseudo gene 2.764 0.0313
LOC641784 AW302767 Similar to ribosomal protein L31, pseudo gene 2.7233 0.04737
FOXP1 NM_032682 Forkhead box P1 2.63004 0.03159
COL27A1 NM_032888 Collagen, type XXVII, alpha 1 2.62832 0.02947
PTMA NM_002823 Prothymosin, alpha 2.58023 0.04672
CALCOCO2 NM_005831 Calcium binding and coiled-coil domain 2 2.53815 0.02005
DNAJB6 NM_005494 DnaJ (Hsp40) homolog, subfamily B, member 6 2.53533 0.02531
LOC391560 XR_018524 Ribosomal protein L32 pseudogene 7 2.43023 0.04685
ZNF234 NM_006630 Zinc finger protein 234 2.37866 0.0357
WASF2 NM_006990 WAS protein family, member 2 2.37554 0.02993
AP3S2 NM_005829 Adaptor-related protein complex 3, sigma 2
subunit
2.36803 0.01003
KLF2 NM_016270 Kruppel-like factor 2 (lung) 2.36563 0.03192
ZC3H11A NM_014827 Zinc finger CCCH-type containing 11A 2.35468 0.02414
RPS16P9 XR_016930 Ribosomal protein S16 pseudogene 9 2.32731 0.00056
EIF1B NM_005875 Eukaryotic translation initiation factor 1B 2.28022 0.00834
NR4A2 NM_006186 Nuclear receptor subfamily 4, group A, member 2 2.25709 0.03943
LY6G6C NM_025261 Lymphocyte antigen 6 complex, locus G6C 2.19288 0.0412
RPS7P5 AK098605 Ribosomal protein S7 pseudogene 5 2.17098 0.00883
RPLP0P2 NR_002775 Ribosomal protein, large, P0 pseudogene 2 2.15877 0.03239
CCDC144A BC034617 Coiled-coil domain containing 144A 2.15257 0.01531
GARS NM_002047 Glycyl-tRNA synthetase 2.14073 0.04554
LOC388524 NM_001005472 Similar to Laminin receptor 1 2.13836 0.04665
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Chemotherapy is important in treating and preventing the
recurrence of ovarian cancer; however, resistance is an
obstacle to overcome and finding new treatment strategies
has become increasingly valuable. High-throughput tech-
nologies for assaying gene expression, such as high-density
oligonucleotide and cDNA microarrays, may offer the
potential to identify clinically relevant genes highly dif-
ferentially expressed between different cell lines. Thus, this
study showed the first communication of an investigation
that involved the genome-wide examination of differences
in gene expression between ovarian cancer cell lines and
their sub-lines with enhanced metastasis and chemothera-
pic resistance. We identified 49 genes that were expressed
differentially between Group A, B, C and Group 1, 2, 3,
and the average change in expression level between the two
groups was at least twofold. The known functions of some
of these genes can provide insights with the highly
metastasis and chemotherapic resistance for ovarian can-
cer, although others are still useful for a further research.
GCET2 is found to be the most up-regulated genes in the
more enhanced metastasis and chemoresistance cell group,
and it is also known as human germinal center associated
lymphoma (HGAL) gene, is specifically expressed in ger-
minal center B-lymphocytes and germinal center-derived B
cell lymphomas [12], but its function is largely unknown.
The GCET2 gene is located on chromosome 3q13 and
encodes a 178-amino acid (aa) protein with 51 % identity
and 62 % similarity to the murine M17 protein [13].
GCET2 is a cytoplasmatic protein that may also associate
with cell membrane. GCET2 expression is associated with
improved survival in diffuse large B cell lymphoma
(DLBCL) and classic Hodgkin lymphoma patients [14].
In vitro studies in human lymphocytes demonstrated that
HGAL increased the binding of myosin to F-actin and
inhibits the ability of myosin to translocate actin by
reducing the maximal velocity of myosin head/actin
movement [15]. In vitro HGAL enhances BCR signaling by
binding and increasing Syk activation, in vivo older HGAL
transgenic animals progressively developed polyclonal
lymphoid hyperplasia and reactive AA amyloidosis [16],
these finding suggests that GCET2 may play a role in
humoral immune responses. No articles about expression
and function of GCET2 on ovarian tissue have been pub-
lished until now, and our findings make a possible insight
of this gene in the study of ovarian cancer, especially about
the aspects of metastasis and chemoresistance.
Cystic fibrosis transmembrane conductance regulator
(CFTR, ABC35 or ABCC7) was found among the most up-
regulated genes in more metastasis and chemoresistance
cell line group, and it participates in the beta-adrenergic-
dependent CFTR expression pathway. Loss of function
mutations of this gene causes the autosomal recessive
lethal disease cystic fibrosis (CF) and congenital bilateral
aplasia of the vas deferens. There is an increasing interest
in the association of cancer incidence with the genetic
variations in the CFTR gene. Large cohort studies in North
American and European patients with CF found that there
was a marked increase in the risk of malignancies affecting
the gastrointestinal tract, even to 17 times higher risk of
digestive cancer with most cases arising in the bowel [17].
Meanwhile, mutations and low-penetrance polymorphisms
in the CFTR gene have been found in patients with various
cancers, including pancreatic cancer [18], breast cancer
[19], cervical cancer [20], melanoma [21], prostate cancer
[22] and lung cancer [23, 24]. On the other hand, CFTR has
been suggested to interact with various cancer-related
kinases [25]. It encodes a member of the ATP-binding
cassette (ABC) transporter superfamily. ABC proteins
transport various molecules across extracellular and intra-
cellular membranes. ABC genes are divided into seven
distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP,
GCN20, White). Meanwhile, CFTR is a member of the
MRP subfamily that is involved in multidrug resistance.
The encoded protein is a cAMP-activated Cl- channel
lining the luminal/apical surfaces of epithelial cells in
airway, gut, and exocrine glands, and there is a functional





ZNF467 NM_207336 Zinc finger protein 467 2.12557 0.04513
LOC732186 XR_016076 Similar to signal sequence receptor gamma
subunit, pseudo gene
2.0591 0.01044
ZBTB43 NM_014007 Zinc finger and BTB domain containing 43 2.05301 0.02564
RPL13AP23 XR_018808 Ribosomal protein L13a pseudogene 23 2.04535 0.00653
RPLP1P7 CH471086 Ribosomal protein, large, P1 pseudogene 7 2.04394 0.00846
RPL31P10 XR_018695 Ribosomal protein L31 pseudogene 10 2.04042 0.03652
SNX29 AK024473 Sorting nexin 29 2.03297 0.04401
LOC648361 XM_001127349 Similar to 40S ribosomal protein S12,
pseudogene
2.00295 0.04577
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coupling between CFTR and MRP2 that may be mediated
by PDZ protein [24]. Taken together, our gene expression
profile that show a significant up-regulated result of CFTR
in more metastasis and chemoresistant ovarian cancer cell
lines are consistent with previous findings, a further
research on the mechanism of CFTR on ovarian cancer or
Fig. 4 Quantitative real-time PCR validation for 4 selected genes.
Quantitative real-time PCR for selected genes (GCET2, NLRP4,
FOXP1 and SNX29) found to be differentially expressed in gene
microarrays. The relative expression of GCET2 and CFTR was
significantly higher in RMG-I-H, COC1/DDP, HO8910/PM than
RMG-I-C, COC1, HO8910, respectively. The relative expression of
FOXP1 and GARS was significantly lower in RMG-I-H, COC1/DDP,
HO8910/PM than RMG-I-C, COC1, HO8910, respectively.
(P \ 0.05, one-way ANOVA)
Table 5 FOXP1 protein
expression in 29 primary
epithelial ovarian cancer (EOC)




EOC 29 17 12
OM 25 21 4
Table 6 FOXP1 protein
expression in 40 chemotherapy-
sensitive epithelial ovarian can-





Sensitive 40 23 17
Resistant 30 25 5
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selective inhibition of CFTR or its pathway may give a
insight in therapeutic effects against metastatic and
chemoresistant of ovarian cancer.
RBMX gene, also known as HnRNP G, is a member of
heterogeneous nuclear ribonucleoprotein (hnRNP) family
and can collaborate with hTra2-beta1 (human transformer-
2-beta1) as sequence-specific transacting factors to exert
antagonistic effects on alternative splicing which is rec-
ognized as a pivotal mechanism in regulation of gene
expression and associated to tumorigenesis and metastasis
of a wide variety of human cancers [26]. It is proposed that
the ratio of hnRNP G/hTra2-beta1 influenced cellular
splicing preference [27, 28]. Some researches revealed that
hnRNP G-protein showed as tumor suppressor in endo-
metrial carcinoma [27] and oral squamous cancer [29], its
activity was elicited by transactivating tumor suppressor
Txnip gene [30]. A recent research showed that high fre-
quency of hnRNP G-protein reduction and loss of expres-
sion in precancerous and human oral squamous cell
carcinoma tissue specimens, suggesting that reduction in
hnRNP G may play an important role in the early patho-
genesis of oral squamous cell carcinomas [31].
GPRC6A encodes an orphan G-protein-coupled recep-
tor, mediates the non-genomic effects of testosterone and
other anabolic steroids in multiple tissue, and it is a
potential target for developing antagonists and agonists that
would have broad applications in health and disease [32],
including cancer. A genome-wide association study on
prostate cancer identified GPRC6A was one of the five
novel genetic loci associated with prostate cancer in Jap-
anese and Chinese Han population [33, 34], and the same
result was verified by a genome-wide testing of putative
functional exonic variants in a multiethnic population [35].
GPRC6A is expressed at higher levels in human prostate
cancer cells and prostate cancer tissues and small inter-
fering RNA knockdown of GPRC6A attenuates these
response in human prostate cancer cell lines [36]. GPRC6A
is also coupled to signaling pathways, such as phosphati-
dylinositol 3-kinase that are known to be deregulated in
prostate cancer [32]. On all accounts, nearly all researches
about GPRC6A associated with cancer focused on prostate
cancer, no investigation about this gene on ovarian cancer
has been published.
FOXP1, as one of the down-regulated genes, drew our
attention for a further research. FOXP1 is a FOX family
member consisting of the winged-helix DNA-binding
domain and the N-terminal transcriptional repression
domain, and it is widely expressed and plays a key role in
the development of various human tissues [37, 38]. FOXP1





for FOXP1. Left panel
chemotherapeutic sensitive
sample shows a positive nuclear
staining for FOXP1. Right panel
chemotherapeutic resistant
sample displays a negative
nuclear staining for FOXP1
Fig. 6 Kaplan–Meier survival analysis of chemotherapic ovarian
cancer patients. Kaplan–Meier survival analysis shows that the
positive nuclear staining of FOXP1 is an independent risk factor in
ovarian cancer patients and strongly correlates with good prognosis
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heterodimers with FOXP2 and FOXP4 [39], it has been
suggested to be both a tumor suppressor candidate and
potential oncogene, because of its differential expression
levels in distinctive types of tumors, including B cell
lymphomas [40], breast cancer [41, 42], endometrial cancer
[43], prostate cancer [44], non-small cell lung cancer [38]
and renal cell carcinoma [45], the loss of FOXP1 in breast
cancer has been associated with shorter survival times [42].
Until now, no article about FOXP1 expression in ovarian
cancer has been published, and we made the first investi-
gation of FOXP1 protein expression in ovarian tissue and
found that nuclear staining of FOXP1 decreased as the
metastasis increased, a significant decrease in FOXP1
expression in the resistance group, nuclear FOXP1
expression were independent risk factors strongly corre-
lated with prognosis of ovarian cancer, above all, FOXP1
may serve as a good marker for late stage ovarian cancer
and chemoresistance EOC patients, high expression of
FOXP1 in nucleus is associated with improved survival in
patients with ovarian cancer.
There are some pseudogenes which shows significant
expression difference in enhanced metastasis and chemore-
sistant ovarian cancer cell lines, in which BC031676 and
BC113708 are up-regulated, and RPL28P1, RPL23A,
RPL13AP3, LOC341412, LOC641784, LOC391560,
RPS16P9, LOC732186, RPL13AP23, RPLP1P7,
RPL31P10, LOC648361 are down-regulated, and most of
them are ribosomal protein pseudogenes. Pseudogenes are
DNA sequences similar to genes encoding functional pro-
teins but are presumed to be nonfunctional due to mutations
and truncation by premature stop codons [46]. Ribosomal
protein (RP) pseudogenes constitute the largest family of
pseudogenes (approximately 2000 RP processed pseudo-
genes), and they are constitutively expressed at reasonably
stable levels and are very highly conserved [47]. Although
pseudogenes have long been considered as nonfunctional
genomic sequences, during recent two decades, especially
with the broad applications of next-generation sequencing
technologies, emerging evidences have confirmed that some
pseudogenes have acquired diverse functions in regulating
development and diseases, especially in cancers [48]. Some
pseudogenes are specifically expressed in certain cancers or
diseases. It has been shown that the pseudogene of PTEN,
PTENP1, was selectively lost in some human cancer cells,
resulting in decreased expression of PTEN and abnormal
proliferation of cancer cells [49]. The expression of MY-
LKP1, a duplicated pseudogene of MYLK, can decrease the
stability of MYLK mRNA at the posttranscriptional level and
stimulate cell proliferation [50]. Recently, a study provided a
systematic approach to analyze expressed pseudogenes,
enabling comparisons of cancer versus benign tissues in
multiple solid tumors, which overcome the limitations of
previous analyses of pseudogene expression. They observed
218 pseudogenes expressed only in cancer samples, of which
Table 7 Classification of the
up-regulated and down-
regulated genes involved in the
significant bioprocesses








Gene expression 9.36E-04 11 39.285713 2,187 14.157172
Biopolymer biosynthetic process 0.001659173 10 35.714287 1,972 12.765407
Macromolecule biosynthetic process 0.0031013 10 35.714287 2,141 13.859399
cAMP-mediated signaling 0.00382362 2 7.142857 51 0.33013982
Nucleobase, nucleoside, nucleotide
and nucleic acid metabolic process
0.00942933 10 35.714287 2,495 16.150957
Cyclic-nucleotide-mediated signaling 0.010541212 2 7.142857 86 0.55670637
Transcription 0.014451807 7 25 1,483 9.599948
Biosynthetic process 0.014984685 10 35.714287 2,668 17.270844
G-protein-coupled receptor activity 0.016115764 4 14.285714 546 3.5344381
Translation 0.021661116 3 10.714286 332 2.1491456
Nucleic acid binding 0.030367257 10 35.714287 2,970 19.22579
Biopolymer metabolic process 0.030960111 12 42.857143 3,891 25.187727
Receptor activity 0.036230754 6 21.428572 1,398 9.049715
G-protein-coupled receptor protein
signaling pathway
0.036383796 4 14.285714 702 4.5442777
Second-messenger-mediated signaling 0.042707212 2 7.142857 182 1.178146
Ribonucleoprotein complex 0.046174083 3 10.714286 447 2.8935785
Rhodopsin-like receptor activity 0.04668641 3 10.714286 449 2.9065251
Structural constituent of ribosome 0.0483463 2 7.142857 195 1.2622993
Macromolecule metabolic process 0.049876012 13 46.42857 4,646 30.07509
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P450 Hydroxylations 19 4 2 0.002811053
HIF-1-alpha transcription factor network 88 73 6 0.002937696
Mechanism of acetaminophen activity and toxicity 12 5 2 0.004168975
Hypoxic and oxygen homeostasis regulation of HIF-1-alpha 111 86 6 0.006581206
Cystic fibrosis transmembrane conductance regulator (CFTR) and beta 2
adrenergic receptor (B2AR) pathway
14 3 1 0.006656855
De novo synthesis of IMP 32 4 1 0.011070482
Cytochrome p450 54 9 2 0.01444615
Phase 1 functionalization 87 9 2 0.01444615
il12 and stat4 dependent signaling pathway in th1 development 13 10 2 0.015267268
alpha6beta4integrin 53 50 4 0.01597487
IL4-mediated signaling events 84 52 4 0.018223463
Purine metabolism 100 9 1 0.022020191
Xenobiotics 60 15 2 0.0333969
Stathmin and breast cancer resistance to antimicrotubule agents 18 2 1 0.03385132
Negative regulation of the PI3 K/AKT network 12 2 1 0.03385132
TCR 140 125 6 0.035289083
Gap-filling DNA repair synthesis and ligation in GG-NER 7 2 1 0.038461793
Gap-filling DNA repair synthesis and ligation in TC-NER 7 2 1 0.038461793
FOXA1 transcription factor network 53 40 3 0.04229567
Nucleotide metabolism 198 22 1 0.049933493
Fig. 7 Interaction network of
the differentially expressed
gene. Genes with more links are
shown in bigger size. Proteins
shown in red are encoded by up-
regulated genes, while those in
green are encoded by down-
regulated genes, the gray
represents the predicted genes.
Arrow line represents definite
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178 were observed in multiple cancers, and 40 were found to
have highly specific expression in a single cancer type only,
finally they described ATP8A2-J and CXADR-J pseudogenes
preferentially associated with distinct subsets of breast
cancer and prostate cancer patients, respectively [51].
Besides cancers, pseudogenes also involve in the develop-
ment of other diseases, such as HMGA1-p [52]. Although the
regulatory functions of pseudogenes seem to be striking, the
functional studies of pseudogenes are still in its early stage.
The pseudogenes in our study should not be useless, their
functions and relationships with ovarian cancer, especially
the enhanced metastasis and chemoresistance should be
investigated in near further.
In conclusion, this study has identified potential DEGs
responsible for enhanced metastasis and chemoresistance
in ovarian cancer cell lines. Among the 49 DEGs, 14 genes
were up-regulated and 35 genes were down-regulated.
Prospective investigations using a combination of genomic
and proteomic approaches are required to validate the
functionality of these targets identified.
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